Navigation Links
Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
Date:9/24/2009

r cells. In mice, we were able to reduce significantly the tumour volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," said Dr Melisi.

The use of gemcitabine on its own against the cancer in mice was ineffective because of the drug resistant nature of the disease. However, once it was combined with the TAK-1 inhibitor, Dr Melisi and his colleagues saw a 78% reduction in tumour volumes. "The median average survival for the control, TAK-1 inhibitor, gemcitabine on its own, or TAK-1 inhibitor combined with gemcitabine was 68, 87, 82 and 122 days respectively," he said.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumour and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer. The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer. In the near future, we will study whether it is also able to make other chemotherapeutic agents, such as oxaliplatin, 5-FU or irinotecan, work against pancreatic cancer in mice.

"Our main goal is to translate this combination approach from the bench to the bedside, conducting a clinical trial that could demonstrate the safety of this TAK-1 inhibitor in combination with gemcitabine, and its efficacy, in pancreatic cancer patients."


'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The Lustgarten Foundation Expresses Condolences as Pancreatic Cancer Claims Life of Myles Brand
2. The Lustgarten Foundation Says Patrick Swayzes Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cancer
3. The Pancreatic Cancer Action Network Is Saddened by the Death of Actor Patrick Swayze
4. MicroRNAs circulating in blood show promise as biomarkers to detect pancreatic cancer
5. Pancreatic Cancer Deaths Higher for Blacks
6. Blood Test May Spot Pancreatic Cancer Early
7. Blood Flow Mismatch Seen in Pancreatic Cancers
8. Abnormal Protein May Signal Pancreatic Cancer
9. Blood Type May Boost Pancreatic Cancer Risk
10. Metformin May Lower Diabetics Odds for Pancreatic Cancer
11. Pancreatic cancer risk decreased by one anti-diabetic therapy, increased by others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... As reported by the Statesman Journal in the ... (7/20), police in Salem, MA as well as several other ... heroin epidemic that has taken many lives during the past ... case in which police were able to make two arrests ... pretending to be the victim and claiming to want to ...
(Date:7/25/2014)... (HealthDay News) -- Seniors are more easily distracted during ... study finds. "Almost any type of memory test ... of 25 on," study co-author Randi Martin, professor of ... release. However, Martin said, this study shows that ... older adults compared with younger adults. The study ...
(Date:7/25/2014)... 25, 2014 Reproductive Science Center (RSC) ... Dr. Kerri Luzzo, Lead Physician at RSC Rhode Island, ... professional accomplishments in fertility care and community outreach issued ... 10th Annual PBN Awards ceremony held July 24th at ... the most highly regarded, emerging leaders in their field ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- The human brain ... of dehydration, a new study finds. Although ... in England have found that the brain compensates by ... blood. "This research has helped us understand a ... extreme exercise in extreme conditions," study first author Steven ...
(Date:7/25/2014)... York, ON (PRWEB) July 25, 2014 A ... Michael’s Hospital revealed that 39 percent of all children in ... a dentist. , The survey looked at 2,505 children during the ... all around four years of age. The final result was ... any dental care. Many of these children were from lower-income families ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... By Jenifer Goodwin HealthDay Reporter , ... of parents with health insurance say they haven,t gotten ... new survey in Ohio finds. Parents of kids ... those with public health insurance such as Medicaid or ...
... Medical Center,s Reinberger Neuroscience Intensive Care Unit (NSU) has ... This is a top honor from the American Association ... The NSU joins four other intensive care units ... been recognized with Beacon Awards: Medical Intensive Care ...
... The roots of cassava ( Manihot esculenta ) serve ... of people in many arid regions of the world, ... Unfortunately the roots of commercial cassava cultivars are ... in these regions. In addition to programs designed ...
... HealthDay Reporter , MONDAY, Oct. 4 (HealthDay News) -- ,A ... prompt healthy lifestyle changes in families, new research sUggests. ... program where they were given a list of health-promoting activities ... the family diet, exercising more as a family and reducing ...
... Diagnostic X-rays may increase the risk of developing ... at the University of California, Berkeley,s School of Public ... with acute lymphoid leukemia (ALL) had almost twice the ... X-rays compared with children who did not have leukemia. ...
... When girls with symptoms of autism or ADHD seek professional ... and there is a real risk that they will not ... training is needed in this area,particularly in the public sector, ... thesis focuses primarily on 100 girls who, before reaching adulthood, ...
Cached Medicine News:Health News:Many Kids Not Getting Recommended Care: Survey 2Health News:Many Kids Not Getting Recommended Care: Survey 3Health News:University Hospitals Case Medical Center's neuroscience intensive care unit earns Beacon Award 2Health News:Using cassava to address vitamin A deficiency 2Health News:Companies Can Motivate Families to Live Healthier 2Health News:Companies Can Motivate Families to Live Healthier 3Health News:X-rays linked to increased childhood leukemia risk 2Health News:X-rays linked to increased childhood leukemia risk 3Health News:X-rays linked to increased childhood leukemia risk 4Health News:Girls with autism or ADHD symptoms not taken seriously 2
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
(Date:7/24/2014)... 24, 2014  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2014 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, July 31, 2014 ... business developments. Interested parties may access the ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , June 28 Preliminary results of ... and hypertension demonstrated that the investigational triple combination therapy ... resulted in a statistically significant greater Least Squares (LS) ... 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P ...
... Tolerx, Inc., a biopharmaceutical company developing novel ... T cell activity, today announced the initiation of a ... in autoimmune new-onset type 1 diabetes. The confirmatory Phase ... For Early or New-Onset Type 1 Diabetes) and immediately ...
Cached Medicine Technology:New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 2New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 3New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 4New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 5New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 6New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 7Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 2Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 3Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: